Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Free Cash Flow of -$19.4 million for Q1 2026, down 20.46% on a QoQ basis from -$16.1 million in Q4 2025, and up 44.89% year-over-year from -$13.4 million in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$19.4 million for Q1 2026.
- Quarterly Free Cash Flow rose 44.89% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.7 million (up 34.72% YoY) and the FY2025 annual result came in at -$74.5 million, down 23.36% from the prior year.
- Free Cash Flow was -$19.4 million for Q1 2026 at Arcturus Therapeutics Holdings, down from -$16.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $163.6 million in Q4 2022 and bottomed at -$51.2 million in Q1 2022.
- A 5-year average of -$8.5 million and a median of -$19.4 million in 2026 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow surged 485.04% — and 2025, when it tumbled 5582.75%.
- Arcturus Therapeutics Holdings' Free Cash Flow stood at $163.6 million in 2022, then plunged by 100.92% to -$1.5 million in 2023, then jumped by 81.12% to -$284000.0 in 2024, then tumbled by 5582.75% to -$16.1 million in 2025, then dropped by 20.46% to -$19.4 million in 2026.
- Business Quant data shows ARCT's Free Cash Flow at -$19.4 million in Q1 2026, -$16.1 million in Q4 2025, and -$17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -19.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.44 Mn |
| Mar 31, 2026 | -19.44 Mn |
| Dec 31, 2025 | -16.14 Mn |
| Dec 31, 2025 | -16.14 Mn |
| Sep 30, 2025 | -17.33 Mn |
| Sep 30, 2025 | -17.33 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Mar 31, 2025 | -35.28 Mn |
| Mar 31, 2025 | -35.28 Mn |
| Dec 31, 2024 | -284,000.00 |
| Dec 31, 2024 | -284,000.00 |
| Sep 30, 2024 | -23.84 Mn |
| Sep 30, 2024 | -23.84 Mn |
| Jun 30, 2024 | -30.47 Mn |
| Jun 30, 2024 | -30.47 Mn |
| Mar 31, 2024 | -5.80 Mn |
| Mar 31, 2024 | -5.80 Mn |
| Dec 31, 2023 | -1.50 Mn |
| Dec 31, 2023 | -1.50 Mn |